DNMT3L

Across TCGA pan-cancer cohorts, DNMT3L RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of DNMT3L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where DNMT3L RNA is repressed in tumor relative to normal tissue. In most cancer types DNMT3L is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

KIRC, KIRP, and KICH are the cancer types where DNMT3L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DNMT3L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	−0.425	<.001	11	view →
KIRP	All	III,IV	−0.815	<.001	9	view →
KICH	All	II,III,IV	−0.428	<.001	7	view →
CHOL	All	All	−1.217	<.001	4	view →
LUSC	Female	III,IV	+0.105	.002	3	view →
LIHC	All	II,III,IV	−0.475	.007	2	view →
BRCA	Female	II,III,IV	+0.007	.039	2	view →
COAD	All	III,IV	+0.026	.048	1	view →
LUAD	All	II,III,IV	+0.015	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

DNMT3L–KIRC

Open the KIRC breakdown →